The NHS has negotiated a limit on the amount to be spent on branded medicines, with all excess paid by the pharmaceutical industry.
The new Pharmaceutical Price Regulation Scheme (PPRS), agreed with the Association of the British Pharmacuetical Industry, will provide “predictability and certainty” on the spend for branded medicines, the Department of Health (DH) has claimed.
According to DH, the scheme will encourage the use of innovative and cost effective treatments, strengthening Britain’s life science sector.
The NHS has negotiated a limit on the amount to be spent on branded medicines, with all excess paid by the pharmaceutical industry.
The new Pharmaceutical Price Regulation Scheme (PPRS), agreed with the Association of the British Pharmacuetical Industry, will provide “predictability and certainty” on the spend for branded medicines, the Department of Health (DH) has claimed.
According to DH, the scheme will encourage the use of innovative and cost effective treatments, strengthening Britain’s life science sector.
Lord Earl Howe, Health Minister, said: “This agreement ensures NHS patients will receive the most effective, advanced medicines in the world while managing the cost. I’m delighted that today we have published the full details of the new pricing scheme.
“UK pharmaceutical companies have responded to the challenges we face as a country, both in terms of the increased demand for medicines and pressure on public spending. I hope in return we have given them the certainty and backing they need to flourish as a sector both here and in the global market.”
